Artivion, Inc.（AORT）资讯与事件AORTArtivion, Inc.

Company Reports Q2 Revenue of $125.8M, Beating Expectations

Reports Q2 revenue $125.8M, consensus $120.01M. "In Q2, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio," said CEO Pat Mackin. "...Overall, we are pleased with our Q2 performance, which included an acceleration in stent graft revenue and a return to growth across all international geographies. Combined with the AMDS PMA approval, we have even greater confidence in our ability to deliver our full year guidance. We continue to build our broader market expansion pipeline, with ARTIZEN enrolling as expected, and remain confident in our longer-term growth outlook."

Sees 2026 Adjusted EBITDA of $92M-$99M

Sees 2026 adjusted EBITDA $92M-$99M.

Artivion AMDS Hybrid Prosthesis Approved by FDA

Artivion announced that the U.S. FDA has approved the premarket approval application for the AMDS Hybrid Prosthesis. The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board approval in order to implant AMDS in their institutions, a requirement associated with the Humanitarian Device Exemption. This will reduce administrative burden on hospitals and enabling physicians to treat eligible patients more immediately and broadly across U.S. institutions.